about
What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?Sonography of tumors and tumor-like lesions that mimic carcinoma of the urinary bladderThe prognostic value of histological subtype in patients with metastatic bladder cancerPathobiology and chemoprevention of bladder cancerSignificant Correlation between Chromosomal Aberration and Nuclear Morphology in Urothelial Carcinoma.Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysisMultiphoton microscopy in the evaluation of human bladder biopsies.Urinary bladder cancer in yemen.UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer.Bladder cancer subtypes defined by genomic alterations.The star chart to Ta bladder cancer: an unsophisticated analysis of two-dimensional gel electrophoresis proteome maps.Prostate Brachytherapy seed migration to the Bladder presenting with Gross Hematuria.Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.Primary Signet-Ring Cell Adenocarcinoma of the Urinary Bladder Treated with Partial Cystectomy: A Case Report and Review of the Literature.The relation between Ring Box-1 protein overexpression and tumor grade and stage in bladder urothelial cell carcinoma.Health-related quality of life from a prospective randomised clinical trial of robot-assisted laparoscopic vs open radical cystectomy.Expression of miRNA-630 in bladder urothelial carcinoma and its clinical significance.FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence.Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.A Case of Early Stage Bladder Carcinosarcoma in Late Recurrence of Urothelial Carcinoma after Transurethral Resection.Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC)
P2860
Q26795518-8D520A38-C032-4A2E-88C5-8BC6135A2D64Q30396096-43CC792D-2A8E-4E2F-B3CB-EAB3163703E2Q33709712-2C45661C-3230-48CA-846A-E6896230D28BQ35219328-4A9FBE16-6F43-44E2-8DD7-50C62E54C029Q35865635-6039740D-7053-4D73-8B0A-9A99589763A6Q36117964-FEEC435E-D017-48E5-9C2F-D85C36AEB265Q36807220-96E70655-A0C6-4B31-AF15-454CA77A980DQ37160471-20DFB6F9-2A2A-4285-B12C-EC34B9ECCC27Q37269716-181C6DDB-9E78-418F-92D2-1393018E2C6DQ37278990-49A48FA6-33A8-46F8-89DE-5277FCF36795Q39911414-9AECF5B6-AAB3-40E7-AD8B-DB06529A8B43Q41222136-FB73E694-1980-47C3-A191-B669528BFB22Q44045391-A1AAFD46-13EA-4A8D-B610-8251AB04BC68Q46853658-E2929C41-B54E-4E0F-863D-50FD52903D50Q47548573-D7CE20B6-2871-4825-AFA6-20FA077C0066Q47746077-096ADCD7-1373-48E2-98DB-751E7BE9B560Q48074927-4ED4DBC5-5F7B-42F2-A691-305FC1CF7BA4Q51766901-B3653F6F-518E-4252-BD3A-4256C19E4335Q54215764-692B7BDF-85F0-45D0-A82D-205EB6275D78Q54376271-6B1D9AA4-E33E-4855-8C34-4A0DBC06966EQ54969816-788F3C01-C3DF-4A91-AE07-AFAAD03EA215Q57037510-917C0207-6FBC-4B0E-9C98-0F4CA4E402C2
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bladder cancer: clinical and pathological profile.
@en
Bladder cancer: clinical and pathological profile.
@nl
type
label
Bladder cancer: clinical and pathological profile.
@en
Bladder cancer: clinical and pathological profile.
@nl
prefLabel
Bladder cancer: clinical and pathological profile.
@en
Bladder cancer: clinical and pathological profile.
@nl
P2860
P1476
Bladder cancer: clinical and pathological profile.
@en
P2093
Antonio Lopez-Beltran
P2860
P304
P356
10.1080/03008880802325226
P577
2008-09-01T00:00:00Z